MCID: GLL018
MIFTS: 63

Gallbladder Cancer malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Cancer

Aliases & Descriptions for Gallbladder Cancer:

Name: Gallbladder Cancer 12 50 52 41 14
Gallbladder Carcinoma 12 52 14 69
Malignant Neoplasm of Gallbladder 12 69
Gallbladder Neoplasm 12 69
Malignant Neoplasm of Gallbladder Localized 69
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma of Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 42
Gallbladder Ca 12

Classifications:



Summaries for Gallbladder Cancer

MedlinePlus : 41 your gallbladder is a pear-shaped organ under your liver. it stores bile, a fluid made by your liver to digest fat. as your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. the duct connects your gallbladder and liver to your small intestine. cancer of the gallbladder is rare. it is more common in women and native americans. symptoms include jaundice (yellowing of the skin and whites of the eyes) pain above the stomach fever nausea and vomiting bloating lumps in the abdomen it is hard to diagnose gallbladder cancer in its early stages. sometimes doctors find it when they remove the gallbladder for another reason. but people with gallstones rarely have gallbladder cancer. because it is often found late, it can be hard to treat gallbladder cancer. treatment options include surgery, chemotherapy, radiation, or a combination. nih: national cancer institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to adenosquamous gallbladder carcinoma and gallbladder small cell carcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gallbladder Cancer is MLH1 (MutL Homolog 1), and among its related pathways/superpathways are ERK Signaling and Glioma. The drugs Oxaliplatin and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and skin, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 71 Gallbladder cancer is a relatively uncommon cancer. It has peculiar geographical distribution being... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
id Related Disease Score Top Affiliating Genes
1 adenosquamous gallbladder carcinoma 12.1
2 gallbladder small cell carcinoma 11.1
3 gallbladder adenocarcinoma 10.9
4 cholangiocarcinoma, susceptibility to 10.9
5 gallbladder squamous cell carcinoma 10.8
6 gallbladder papillary carcinoma 10.8
7 bile duct carcinoma 10.8
8 linitis plastica 10.4 CDH1 TP53
9 clear cell adenofibroma 10.4 CDKN2A TP53
10 postpoliomyelitis syndrome 10.4 CDKN2A KRAS TP53
11 malignant mediastinal neurogenic neoplasm 10.3 CEACAM5 TP53
12 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
13 malignant skin fibrous histiocytoma 10.3 CEACAM5 KRAS
14 bronchogenic lung adenocarcinoma 10.3 CEACAM5 MUC1
15 ossifying fibromyxoid tumor 10.3 CDKN2A KRAS TP53
16 familial hypopituitarism 10.3 CDH1 MLH1 TP53
17 breast ductal carcinoma 10.3 CTNNB1 KRAS TP53
18 urethral verrucous carcinoma 10.3 CDKN2A PTGS2 TP53
19 plasmacytoma 10.3 CEACAM5 KRAS TP53
20 sarcomatoid basal cell carcinoma 10.3 CDH1 CEACAM5 TP53
21 adult syndrome 10.3 CTNNB1 KRAS TP53
22 vulva squamous cell carcinoma 10.3 CDKN2A CEACAM5 ERBB2
23 myotonia congenita 10.3 CDKN2A CEACAM5 ERBB2
24 vacterl association with hydrocephaly, x-linked 10.3 AFP CEACAM5
25 adult neuronal ceroid lipofuscinosis 10.3 CDH1 PTGS2 TIMP2
26 differentiating neuroblastoma 10.3 CDH1 CEACAM5 MUC1
27 pineal region mature teratoma 10.3 EGFR ERBB2
28 uterine cervix leukoplakia 10.3 CDKN2A FHIT TP53
29 gastric cancer, somatic 10.3 CDH1 ERBB2 KRAS
30 exudative glomerulonephritis 10.3 EGFR KRAS TP53
31 wolffian duct adenoma 10.3 CEACAM5 KRAS MLH1
32 papilloma 10.3 CTNNB1 MLH1 MUC1
33 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
34 wolffian adnexal neoplasm 10.3 EGFR TP53
35 thymus squamous cell carcinoma 10.3 CDKN2A EGFR TP53
36 uterine disease 10.3 AFP CDKN2A TP53
37 intermediate malignant teratoma 10.3 CDKN2A EGFR KRAS
38 secondary hyperparathyroidism of renal origin 10.3 CDKN2A EGFR TP53
39 inhibited male orgasm 10.3 AFP KRAS TP53
40 immunodeficiency due to a classical component pathway complement deficiency 10.3 CDKN2A EGFR MUC1
41 lacrimal gland mucoepidermoid carcinoma 10.3 CEACAM5 MUC1
42 mitochondrial encephalomyopathy 10.3 CDKN2A PTGS2 TP53
43 uterine corpus endometrial stromal sarcoma 10.3 CEACAM5 KRAS MLH1 TP53
44 extra-adrenal pheochromocytoma 10.3 KRAS PTGS2 TP53
45 cryoglobulinemia 10.3 CDKN2A FHIT TP53
46 rete testis adenoma 10.3 AFP CEACAM5
47 brain stem medulloblastoma 10.3 CCND1 CDKN2A TP53
48 cervical verrucous carcinoma 10.3 CCND1 CDKN2A TP53
49 rectum sarcoma 10.3 CEACAM5 KRAS MLH1 TP53
50 cholecystitis 10.3

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 TIMP2 CTNNB1 EGFR KRAS MUC1
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 CTNNB1 EGFR ERBB2 MUC1 TIMP2

MGI Mouse Phenotypes related to Gallbladder Cancer:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.41 AFP CCND1 CDH1 CDKN2A CTNNB1 EGFR
2 homeostasis/metabolism MP:0005376 10.41 AFP CCND1 CDH1 CDKN2A CTNNB1 EGFR
3 cellular MP:0005384 10.35 CTNNB1 EGFR ERBB2 KRAS MLH1 MUC2
4 digestive/alimentary MP:0005381 10.34 CDKN2A CTNNB1 EGFR ERBB2 FHIT KRAS
5 hematopoietic system MP:0005397 10.34 PTGS2 TIMP2 TP53 ZFX CCND1 CDKN2A
6 immune system MP:0005387 10.34 CCND1 CDH1 CDKN2A CTNNB1 EGFR FHIT
7 mortality/aging MP:0010768 10.34 AFP CCND1 CDH1 CDKN2A CTNNB1 EGFR
8 behavior/neurological MP:0005386 10.32 CDKN2A CTNNB1 ERBB2 KRAS MLH1 PSCA
9 cardiovascular system MP:0005385 10.32 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
10 neoplasm MP:0002006 10.28 CTNNB1 EGFR ERBB2 FHIT KRAS MGMT
11 integument MP:0010771 10.22 CDKN2A CTNNB1 EGFR ERBB2 FHIT KRAS
12 embryo MP:0005380 10.2 CDH1 CDKN2A CTNNB1 EGFR ERBB2 KRAS
13 normal MP:0002873 10.02 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRAS
14 liver/biliary system MP:0005370 10 AFP CDKN2A CTNNB1 EGFR KRAS PTGS2
15 no phenotypic analysis MP:0003012 9.97 CDH1 CDKN2A CTNNB1 EGFR KRAS MGMT
16 reproductive system MP:0005389 9.93 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
17 pigmentation MP:0001186 9.65 CDKN2A CTNNB1 EGFR KRAS TP53
18 respiratory system MP:0005388 9.65 CTNNB1 EGFR ERBB2 KRAS MGMT MLH1
19 vision/eye MP:0005391 9.23 CCND1 CDKN2A CTNNB1 EGFR KRAS MLH1

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 247)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Desflurane Approved Phase 4 57041-67-5 42113
4
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
5
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
7
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
8
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
9 tannic acid Approved, Nutraceutical Phase 4
10 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
13 Analgesics Phase 4,Phase 3,Phase 1
14 Analgesics, Non-Narcotic Phase 4,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Antirheumatic Agents Phase 4,Phase 1
18 Cyclooxygenase 2 Inhibitors Phase 4
19 Cyclooxygenase Inhibitors Phase 4
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Anesthetics Phase 4,Phase 3
23 Anesthetics, General Phase 4,Phase 3
24 Anesthetics, Inhalation Phase 4
25 Central Nervous System Depressants Phase 4,Phase 3
26 Platelet Aggregation Inhibitors Phase 4,Phase 3
27 Neuromuscular Agents Phase 4,Phase 2,Phase 1
28 Neuromuscular Blocking Agents Phase 4,Phase 2,Phase 1
29 Neuromuscular Nondepolarizing Agents Phase 4
30 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
31
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
32
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
33
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
34
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
35
Somatostatin Approved Phase 3 38916-34-6, 51110-01-1 53481605
36
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
37
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40
Ondansetron Approved Phase 3 99614-02-5 4595
41
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
42
Morphine Approved, Investigational Phase 3 57-27-2 5288826
43
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
44
lanreotide Approved Phase 3 108736-35-2
45
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
46
Adenosine Approved, Investigational Phase 3 58-61-7 60961
47
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
48
Citalopram Approved Phase 3 59729-33-8 2771
49
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 211)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Pain Post Abdominal Laparoscopy Prevention With Arcoxia Completed NCT00565682 Phase 4
4 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Recruiting NCT02057679 Phase 4
5 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Recruiting NCT02174575 Phase 4
6 Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery Recruiting NCT02812186 Phase 4
7 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
8 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3
9 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3
10 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3
11 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3
12 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3
13 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3
14 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
16 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
17 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
18 Heart and Estrogen-Progestin Replacement Study (HERS) Completed NCT00319566 Phase 3
19 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3
20 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3
21 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3
22 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Recruiting NCT01926236 Phase 3
23 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3
24 Comparison of Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy Recruiting NCT02595086 Phase 3
25 Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer Recruiting NCT02490111 Phase 3
26 Pentoxifylline Treatment in Acute Pancreatitis (AP) Enrolling by invitation NCT02487225 Phase 3
27 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Not yet recruiting NCT02867865 Phase 2, Phase 3
28 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Not yet recruiting NCT03093870 Phase 2, Phase 3
29 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3
30 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3
31 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3
32 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3
33 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3
34 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2
35 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2
36 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2
37 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
38 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2
39 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2
40 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2
41 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2
42 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2
43 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2
44 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2
45 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
46 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2
47 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2
48 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2
49 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2
50 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

MalaCards organs/tissues related to Gallbladder Cancer:

39
Liver, Lymph Node, Skin, Eye, Small Intestine, Endothelial, Pancreas

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

18
The Gallbladder

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 702)
id Title Authors Year
1
To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer? ( 28090223 )
2017
2
The NmrA-like family domain containing 1 pseudogene Loc344887 is amplified in gallbladder cancer and promotes epithelial-mesenchymal transition. ( 28245089 )
2017
3
The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. ( 27894946 )
2017
4
Epigenetic Downregulation of PTEN in Gallbladder Cancer. ( 28124240 )
2017
5
Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1I+ via miR-138. ( 28077595 )
2017
6
Comparative Analysis of Mutational Profile of Sonic hedgehog Gene in Gallbladder Cancer. ( 28058596 )
2017
7
Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells. ( 28070171 )
2017
8
Healthy dietary patterns and incidence of biliary tract and gallbladder cancer in a prospective study of women and men. ( 27870981 )
2017
9
Acute cholecystitis, chronic cholecystitis or gallbladder cancer? ( 28073581 )
2017
10
Re: Incidental Gallbladder Cancer Visualized From Posttreatment 131I Whole-Body Scan. ( 28079570 )
2017
11
Incidence rate for gallbladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. ( 28064205 )
2017
12
The clinical significance and underlying correlation of pStat-3 and integrin I+vI^6 expression in gallbladder cancer. ( 28061445 )
2017
13
Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study. ( 27575712 )
2016
14
Spontaneous Hepatic Infarction in a Patient with Gallbladder Cancer. ( 27462232 )
2016
15
Annexin A4-nuclear factor-I_B feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. ( 27491820 )
2016
16
CYP1A1, GSTM1, GSTT1 and TP53 Polymorphisms and Risk of Gallbladder Cancer in Bolivians. ( 26925680 )
2016
17
Incidental gallbladder cancer diagnosed on cholecystectomy specimens: a study of 30 cases. ( 28051219 )
2016
18
Aggressive Surgery for Locally Advanced Gallbladder Cancer with Obstructive Jaundice: Result of a Prospective Study. ( 26918527 )
2016
19
Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. ( 27864927 )
2016
20
Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival. ( 26715268 )
2016
21
Long Noncoding RNA GCASPC, a Target of miR-17-3p, Negatively Regulates Pyruvate Carboxylase-Dependent Cell Proliferation in Gallbladder Cancer. ( 27450454 )
2016
22
Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer. ( 27084680 )
2016
23
A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. ( 27620744 )
2016
24
Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer. ( 26812694 )
2016
25
CCR7 mediates the TNF-I+-induced lymphatic metastasis of gallbladder cancer through the "ERK1/2 - AP-1" and "JNK - AP-1" pathways. ( 27009073 )
2016
26
LASP-1 induces proliferation, metastasis and cell cycle arrest at the G2/M phase in gallbladder cancer by down-regulating S100P via the PI3K/AKT pathway. ( 26797416 )
2016
27
A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. ( 26949052 )
2016
28
To improve outcomes of gallbladder cancer we need to better understand it! ( 27500397 )
2016
29
Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease. ( 27623942 )
2016
30
miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. ( 26852750 )
2016
31
The efficacy of contrast-enhanced harmonic endoscopic ultrasonography in diagnosing gallbladder cancer. ( 27162097 )
2016
32
A case of possible paraneoplastic neurological syndrome presenting as multiple cranial nerve palsies associated with gallbladder cancer. ( 27498818 )
2016
33
Incidental gallbladder cancer after cholecystectomy: 1990 to 2014. ( 27540304 )
2016
34
Individualized nomogram improves diagnostic accuracy of stage I-II gallbladder cancer in chronic cholecystitis patients with gallbladder wall thickening. ( 27020635 )
2016
35
Unexpected gallbladder cancer: Surgical strategies and prognostic factors. ( 27648157 )
2016
36
Corrigendum to <LASP-1 induces proliferation, metastasis and cell cycle arrest at the G2/M phase in gallbladder cancer by down-regulating S100P via the PI3K/AKT pathway> <Cancer Lett. 372 (2016) 239-250>. ( 27125425 )
2016
37
Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206. ( 27191262 )
2016
38
Current Status on Cholangiocarcinoma and Gallbladder Cancer. ( 27995089 )
2016
39
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer. ( 27092878 )
2016
40
Rescued expression of WIF-1 in gallbladder cancer inhibits tumor growth and induces tumor cell apoptosis with altered expression of proteins. ( 27430608 )
2016
41
Association of Methylenetetrahydrafolate Reductase Gene Polymorphism (MTHFR) in Patients with Gallbladder Cancer. ( 26687138 )
2016
42
TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. ( 26992854 )
2016
43
Body Mass Index Can Increase the Risk of Gallbladder Cancer: A Meta-Analysis of 14 Cohort Studies. ( 27899789 )
2016
44
Technical Aspects of Gallbladder Cancer Surgery. ( 27017862 )
2016
45
Risk Factors for Gallbladder Cancer in Nepal a Case Control Study. ( 27509990 )
2016
46
Re: Incidental Gallbladder Cancer Visualized From Posttreatment 131I Whole-Body Scan. ( 27922868 )
2016
47
Does a second resection provide a survival benefit in patients diagnosed with incidental T1b/T2 gallbladder cancer following cholecystectomy? ( 27986417 )
2016
48
IL17 producing I^I'T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. ( 27062572 )
2016
49
Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. ( 27173614 )
2016
50
Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. ( 27150440 )
2016

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
4 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
5 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
6 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
9 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
2
Show member pathways
13.02 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
3
Show member pathways
12.93 CCND1 CTNNB1 EGFR ERBB2 KRAS PTGS2
4
Show member pathways
12.81 CDH1 CTNNB1 ERBB2 KRAS PTGS2 TP53
5
Show member pathways
12.62 CTNNB1 EGFR ERBB2 KRAS TP53
6 12.54 CCND1 CDKN2A EGFR ERBB2 KRAS PTGS2
7 12.53 CCND1 CDKN2A MGMT MLH1 TP53
8
Show member pathways
12.5 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRAS
9 12.45 CCND1 CDH1 CTNNB1 PTGS2 TP53
10
Show member pathways
12.44 CTNNB1 EGFR ERBB2 KRAS TP53
11 12.42 CCND1 CDKN2A CTNNB1 KRAS TP53
12 12.37 CCND1 CDH1 CDKN2A TP53
13
Show member pathways
12.33 CCND1 EGFR ERBB2 PTGS2
14 12.33 CCND1 CTNNB1 EGFR ERBB2 KRAS TP53
15
Show member pathways
12.31 CCND1 EGFR ERBB2 KRAS TP53
16 12.3 CCND1 CDKN2A KRAS TP53
17
Show member pathways
12.28 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRAS
18 12.25 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
19 12.18 AFP CCND1 CDH1 CTNNB1
20
Show member pathways
12.18 CCND1 EGFR ERBB2 KRAS TP53
21 12.16 CCND1 CDH1 CTNNB1 EGFR KRAS TP53
22
Show member pathways
12.14 CCND1 CTNNB1 EGFR ERBB2
23
Show member pathways
12.1 CCND1 CDKN2A EGFR ERBB2 KRAS TP53
24 12.09 AFP EGFR MLH1 TP53
25
Show member pathways
12.09 CCND1 EGFR ERBB2 KRAS
26 12.06 CCND1 CDKN2A KRAS MGMT MLH1 TP53
27 12.03 CCND1 EGFR PTGS2 TP53
28 12.01 CCND1 CTNNB1 KRAS TP53
29 11.99 CCND1 MUC1 PTGS2 TP53
30 11.98 CCND1 CDH1 CTNNB1 EGFR KRAS MLH1
31 11.97 CCND1 CDKN2A CTNNB1 ERBB2 KRAS TP53
32 11.96 CDH1 CEACAM5 CTNNB1 MUC1
33 11.85 CCND1 CDKN2A CTNNB1 EGFR KRAS MGMT
34 11.83 CCND1 FHIT PTGS2 TP53
35 11.78 CCND1 CDH1 CTNNB1
36 11.76 CDKN2A ERBB2 MLH1 TP53
37 11.74 CDH1 CTNNB1 EGFR ERBB2
38 11.71 CTNNB1 EGFR ERBB2
39 11.69 EGFR ERBB2 KRAS TP53
40 11.62 EGFR ERBB2 KRAS
41 11.58 CCND1 PTGS2 TP53
42 11.57 CCND1 CDKN2A EGFR TP53
43 11.55 EGFR KRAS PTGS2
44 11.45 CDH1 CTNNB1 EGFR
45 11.44 CEACAM5 MUC1 TIMP2
46 11.35 CCND1 CDH1 CTNNB1
47 11.34 CTNNB1 EGFR TP53
48 11.31 CTNNB1 EGFR ERBB2 KRAS
49 11.3 CDH1 EGFR ERBB2
50 11.23 CCND1 CDH1 CTNNB1 KRAS TP53

GO Terms for Gallbladder Cancer

Cellular components related to Gallbladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.16 CDH1 CTNNB1
2 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
3 basolateral plasma membrane GO:0016323 8.92 CEACAM5 CTNNB1 EGFR ERBB2

Biological processes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.91 CDKN2A CTNNB1 PTGS2 TIMP2 TP53
2 liver development GO:0001889 9.75 CCND1 EGFR KRAS
3 positive regulation of protein phosphorylation GO:0001934 9.73 CCND1 EGFR ERBB2 KRAS
4 response to glucocorticoid GO:0051384 9.71 CCND1 KRAS PTGS2
5 Ras protein signal transduction GO:0007265 9.7 CDKN2A KRAS TP53
6 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR ERBB2 KRAS
7 cellular response to growth factor stimulus GO:0071363 9.63 CTNNB1 EGFR ERBB2
8 response to organic cyclic compound GO:0014070 9.62 CCND1 EGFR MGMT PTGS2
9 entry of bacterium into host cell GO:0035635 9.57 CDH1 CTNNB1
10 replicative senescence GO:0090399 9.56 CDKN2A TP53
11 mitotic G1 DNA damage checkpoint GO:0031571 9.55 CCND1 TP53
12 positive regulation of cellular senescence GO:2000774 9.49 CDKN2A KRAS
13 ERBB2 signaling pathway GO:0038128 9.43 EGFR ERBB2 KRAS
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.4 CDKN2A ERBB2
15 cellular response to indole-3-methanol GO:0071681 9.37 CDH1 CTNNB1
16 response to estradiol GO:0032355 9.26 CCND1 CTNNB1 EGFR PTGS2
17 response to UV-A GO:0070141 9.16 CCND1 EGFR
18 response to drug GO:0042493 9.1 CCND1 CDH1 CTNNB1 MGMT PTGS2 TIMP2

Molecular functions related to Gallbladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 CCND1 CDKN2A CTNNB1 EGFR TP53
2 enzyme binding GO:0019899 9.35 CCND1 CTNNB1 EGFR PTGS2 TP53
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR ERBB2
4 protein phosphatase binding GO:0019903 8.92 CTNNB1 EGFR ERBB2 TP53

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....